Evaluation of two, commercial, multi‐dye, nucleic acid amplification technology tests, for HBV/HCV/HIV‐1/HIV‐2 and B19V/HAV, for screening blood and plasma for further manufacture

Background  The cobas® TaqScreen MPX Test, version 2.0, a multiplex, multi‐dye nucleic acid amplification technology (NAT) test from Roche was evaluated by two European Blood Banks, the German Red Cross Blood Donor Service, Frankfurt, Germany and Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain. In addition, the cobas® TaqScreen DPX Test was evaluated for the simultaneous detection and quantitation of parvovirus B19 and the detection of hepatitis A virus (HAV).

[1]  J. Saldanha,et al.  Multicenter evaluation of a commercial multiplex polymerase chain reaction test for screening plasma donations for parvovirus B19 DNA and hepatitis A virus RNA , 2012, Transfusion.

[2]  H. Ullum,et al.  International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009 , 2012, Vox sanguinis.

[3]  E. Seifried,et al.  Recipients potentially infected with parvovirus B19 by red blood cell products , 2011, Transfusion.

[4]  P. Torres,et al.  Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain , 2010, Transfusion.

[5]  M K Hourfar,et al.  Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes , 2010, Vox sanguinis.

[6]  M. Rapicetta,et al.  Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors. , 2009, The Journal of infection.

[7]  P. Gallian,et al.  Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201 , 2009, Transfusion.

[8]  P. Gallian,et al.  Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti‐HCV, anti‐HIV, and p24/anti‐HIV combination assays in seroconversion panels , 2009, Transfusion.

[9]  E. Vila,et al.  Donor screening for hepatitis B virus infection in a cell and tissue bank , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[10]  A. Gröner.  Pathogen safety of plasma‐derived products – Haemate® P/Humate‐P® , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  Lei Li,et al.  A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus , 2008, Transfusion.

[12]  E. Seifried,et al.  Blood donor screening for parvovirus B19 in Germany and Austria , 2007, Transfusion.

[13]  A. Keller,et al.  Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA , 2007, Transfusion.

[14]  J. Allain,et al.  Characterization of HBV DNA+/HBsAg− blood donors in Poland identified by triplex NAT , 2006, Hepatology.

[15]  J. Echevarría,et al.  Acute hepatitis B virus window‐period blood donations detected by individual‐donation nucleic acid testing: a report on the first two cases found and interdicted in Spain , 2006, Transfusion.

[16]  M. Schmidt,et al.  Evaluation of an automated high‐volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment , 2005, Vox sanguinis.

[17]  A. Heath,et al.  A World Health Organization International Standard for hepatitis A virus RNA nucleic acid amplification technology assays , 2005, Vox sanguinis.

[18]  A. Heitmann,et al.  Occurrence of hepatitis A virus genotype III in Germany requires the adaptation of commercially available diagnostic test systems , 2005, Transfusion.

[19]  A. Berger,et al.  High-throughput purification of viral RNA based on novel aqueous chemistry for nucleic acid isolation. , 2005, Clinical chemistry.

[20]  P. Minor,et al.  Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. , 2004, Journal of virological methods.

[21]  M. Kleines,et al.  Efficient Extraction of Viral DNA and Viral RNA by the Chemagic Viral DNA/RNA Kit Allows Sensitive Detection of Cytomegalovirus, Hepatitis B Virus, and Hepatitis G Virus by PCR , 2003, Journal of Clinical Microbiology.

[22]  S. Laperche,et al.  Genetic Diversity within Human Erythroviruses: Identification of Three Genotypes , 2002, Journal of Virology.

[23]  J. Hernández,et al.  Estimated risk of transfusion‐transmitted viral infections in Spain , 2002, Transfusion.

[24]  E. Seifried,et al.  The German experience with NAT , 2002, Transfusion medicine.

[25]  E. Seifried,et al.  Yield of HCV and HIV‐1 NAT after screening of 3.6 million blood donations in central Europe , 2002, Transfusion.

[26]  A. Heath,et al.  Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques , 2002, Vox sanguinis.

[27]  E. Seifried,et al.  Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting , 1999, The Lancet.

[28]  J. Barbara,et al.  Blood donor screening for parvovirus B19. , 1990, Journal of virological methods.

[29]  E Seifried,et al.  Status of NAT screening for HCV, HIV and HBV--experiences of the German Red Cross Blood Donation Services. , 2002, Developments in biologicals.